Treatment of Histologic Transformation
- PMID: 32586581
- DOI: 10.1016/j.hoc.2020.03.001
Treatment of Histologic Transformation
Abstract
Histologic transformation from follicular lymphoma to aggressive lymphoma historically had a poor prognosis. Routine use of anti-CD20 antibody rituximab has changed the landscape of follicular lymphoma (FL) such that outcomes are improved in select patients, similar to de-novo diffuse large B-cell lymphoma. Several biological and clinical biomarkers can predict risk of transformation, and ongoing research is improving understanding of the biology surrounding the transformation process. This review provides an overview of risk factors, prognosis, and treatment of histologic transformation of FL.
Keywords: Follicular lymphoma; Histologic transformation; Prognosis; Therapy; Transformed lymphoma.
Copyright © 2020 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
